Vitreous and Serum Concentrations of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Proliferative Diabetic Retinopathy

Figures & data

Table 1 Patients’ Characteristics

Variable	Value	Groups
		PDR	Control
Gender
Male	12	8	4
Female	10	9	1
Eyes
Right	8	6	2
Left	14	11	3
BCVA
0–3/60	19	15	4
>3/60	3	2	1
Hypertension
Yes	9	9	0
No	13	8	5
Age (years)	52.64±10.1	52.29±10.74	53.80±8.47
IOP (mmHg)	13.86±2.1	13.82±2.30	14.00±1.60
Blood Glucose (mg/dl)	161±74.34	179.00±75.50	99.80±12.00

Notes: The data are expressed as number and mean±SD (according to data variable).

Abbreviations: PDR, proliferative diabetic retinopathy; BCVA, best-corrected visual acuity; IOP, intraocular pressures.

Table 2 The VEGF-A and PDGF-AB Concentrations

Variable		Group		P
		PDR (pg/mL)	Control (pg/mL)
VEGF- A	Vitreous	630.72±342.81	153.58±145.85	0.001*
	Serum	551.38±461.84	577.85±336.29	0.493
PDGF-AB	Vitreous	119.43±56.21	63.67±23.40	0.031*
	Serum	98.69±38.56	140.13±80.93	0.319

Notes: The data are expressed as mean±SD. *Significant difference between PDR and control group using Mann–Whitney test (P<0.05).

Abbreviations: PDR, proliferative diabetic retinopathy; VEGF-A, vascular endothelial growth factor-A; PDGF-AB, platelet-derived growth factor-AB.

Table 3 The VEGF-A and PDGF-AB Concentration Ratios on Vitreous and Serum

Ratio Variable	Variable	PDR	Control	P
Vitreous/Serum	VEGF-A	2.1±1.8	0.31±0.33	0.005*
	PDGF-AB	1.32±0.68	0.66±0.52	0.058
VEGF-A/PDGF-AB	Vitreous	6.21±4.03	2.66±2.15	0.071
	Serum	5.82±5.3	6.39±5.96	0.940

Notes: The data are expressed as mean±SD. *Significant difference between PDR and control group using Mann–Whitney test (P<0.05).

Abbreviations: PDR, proliferative diabetic retinopathy; VEGF-A, vascular endothelial growth factor-A; PDGF-AB, platelet-derived growth factor-AB.

Figure 1 The Vitreous VEGF-A and PDGF-AB concentrations in each PDR group.

Notes: Group classifications, I: PDR with VH; II: PDR with VH and fibrotic tissues; III: PDR with TRD. *Significant difference using Post hoc Bonferroni test (P<0.05).

Abbreviations: PDR, proliferative diabetic retinopathy; VH, vitreous hemorrhage; TRD, tractional retinal detachment; VEGF-A, vascular endothelial growth factor-A; PDGF-AB, platelet-derived growth factor-AB.

Table 4 The VEGF-A and PDGF-AB Concentration Ratios in Vitreous and Serum in Each PDR Group

Ratio Variable	PDR Groups	Ratio	P
VEGF-A/PDGF-AB Vitreous	I	8.04±2.62	*0.008
	II	2.54±1.26
	III	7.45±4.94
VEGF-A/PDGF-AB Serum	I	4.85±2.54	0.591
	II	3.83±2.91
	III	8.43±7.95
VEGF-A Vitreous/Serum	I	2.43±1.97	0.754
	II	1.53±1.07
	III	2.25±2.25
PDGF-AB Vitreous/Serum	I	1.06±0.50	0.482
	II	1.72±1.02
	III	1.25±0.39

Notes: The data are expressed as mean±SD. Group classifications, I: PDR with VH; II: PDR with VH and fibrotic tissues; III: PDR with TRD. *Significant difference using Kruskal-Wallis test among all PDR groups (P<0.05)

Abbreviations: PDR, proliferative diabetic retinopathy; VH, vitreous hemorrhage; TRD, tractional retinal detachment; VEGF-A, vascular endothelial growth factor-A; PDGF-AB, platelet-derived growth factor-AB.